Komori
Annual Securities Report4888STELLA PHARMA CORPORATIONPharmaceuticals

Annual Securities Report — FY2025

What STELLA PHARMA CORPORATION reported for the period from 2025-04-01 to 2026-03-31.

How much it says
47Typical
What moved here
32named for the first time
Its own wording
56terms
Which filing this is
15/ 15newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

Following the entry of its major manufacturing contractor into bankruptcy proceedings in September 2025, the company reviewed its manufacturing structure and proceeded to rebuild a stable supply system by entering into a development and contract manufacturing agreement with a new contractor. For the fiscal year ended March 2026, it reported net sales of ¥323.389 million and a net loss of ¥780.917 million, while continuing R&D investment of ¥301.914 million.

Komori's summary of this document, not the document's own words.
47Typical
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
Magnitude of Change
45
Typical
Strategic Shift
49
Typical
Capital Movements
38
Thin
Disclosure Gaps
0
Almost nothing
Concentration Risk
15
Almost nothing
Future Commitments
68
Detailed
Change in Risk
55
Typical
Financial and Capital Policy
100
Very detailed
Specificity of Disclosure
7
Almost nothing
Product portfolio
55
Typical
Technology Position
50
Typical
Confidence in Strategic Bets
R&D spend3億円Money spent making new things.
Cash left over3億円Cash from the business, less what went into equipment.
Spent on equipment3百万円Plants, machines — things meant to last.
Employees47Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
STELLA PHARMA CORPORATION — FY2025 | Komori